[1] QIN J, ZHOU Z, CHEN W, et al. BAP1 promotes breast cancer cell proliferation and metastasis by deubiquitinating KLF5
[J]. Nat Commun, 2015, 6:8471.

[2] KOMANDER D, CLAGUE M J, URBE S. Breaking the chains: structure and function of the deubiquitinases
[J]. Nat Rev Mol Cell Biol, 2009, 10(8):550-63.

[3] LIM K H, SONG M H, BAEK K H. Decision for cell fate: deubiquitinating enzymes in cell cycle checkpoint
[J]. Cell Mol Life Sci, 2016, 73(7):1439-55.

[4] JENSEN D E, PROCTOR M, MARQUIS S T, et al. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression
[J]. Oncogene, 1998, 16(9):1097-112.

[5] CARBONE M, YANG H, PASS H I, et al. BAP1 and cancer
[J]. Nat Rev Cancer, 2013, 13(3):153-9.

[6] ESTAVOYER B, MESSMER C, ECHBICHEB M, et al. Mechanisms orchestrating the enzymatic activity and cellular functions of deubiquitinases
[J]. J Biol Chem, 2022, 298(8):102198.

[7] BREKKEN R A. Loss of BAP1 Leads to More YAPing in Pancreatic Cancer
[J]. Cancer Res, 2020, 80(8):1624-1625.

[8] SHAHRIYARI L, ABDEL-RAHMAN M, CEBULLA C. BAP1 expression is prognostic in breast and uveal melanoma but not colon cancer and is highly positively correlated with RBM15B and USP19
[J]. PLoS One, 2019, 14(2):e0211507.

[9] TANG J, LI Y, SANG Y, et al. LncRNA PVT1 regulates triple-negative breast cancer through KLF5/beta-catenin signaling
[J]. Oncogene, 2018, 37(34):4723-4734.

[10] ZARRIZI R, MENARD J A, BELTING M, et al. Deubiquitination of gamma-tubulin by BAP1 prevents chromosome instability in breast cancer cells
[J]. Cancer Res, 2014, 74(22):6499-508.

[11] YAN L, YU M C, GAO G L, et al. MiR-125a-5p functions as a tumour suppressor in breast cancer by downregulating BAP1
[J]. J Cell Biochem, 2018, 119(11):8773-8783.

[12] KALIRAI H, DODSON A, FAQIR S, et al. Lack of BAP1 protein expression in uveal melanoma is associated with increased metastatic risk and has utility in routine prognostic testing
[J]. Br J Cancer, 2014, 111(7):1373-80.

[13] PENA-LLOPIS S, VEGA-RUBIN-DE-CELIS S, LIAO A, et al. BAP1 loss defines a new class of renal cell carcinoma
[J]. Nat Genet, 2012, 44(7):751-9.

[14] CHEN X, HUANG A, WANG Y, et al. BRCA1-associated protein 1 serves as a tumor suppressor in hepatocellular carcinoma by deubiquitinating and stabilizing PTEN
[J]. Am J Cancer Res, 2021, 11(5):2044-2061.

[15] MAYO S C, PAWLIK T M. Current management of colorectal hepatic metastasis
[J]. Expert Rev Gastroenterol Hepatol, 2009, 3(2):131-44.

[16] DUFFY M J, VAN DALEN A, HAGLUND C, et al. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use
[J]. Eur J Cancer, 2007, 43(9):1348-60.

[17] JIA Y, GUO M. Epigenetic changes in colorectal cancer
[J]. Chin J Cancer, 2013, 32(1):21-30.

[18] TANG J, XI S, WANG G, et al. Prognostic significance of BRCA1-associated protein 1 in colorectal cancer
[J]. Med Oncol, 2013, 30(2):541.

[19] PERKAIL S, ANDRICOVICH J, KAI Y, et al. BAP1 is a haploinsufficient tumor suppressor linking chronic pancreatitis to pancreatic cancer in mice
[J]. Nat Commun, 2020, 11(1):3018.

[20] LEE H J, PHAM T, CHANG M T, et al. The Tumor Suppressor BAP1 Regulates the Hippo Pathway in Pancreatic Ductal Adenocarcinoma
[J]. Cancer Res, 2020, 80(8):1656-1668.

[21] DENG R, GUO Y, LI L, et al. BAP1 suppresses prostate cancer progression by deubiquitinating and stabilizing PTEN
[J]. Mol Oncol, 2021, 15(1):279-298.

[22] PARK C M, LEE J E, KIM J H. BAP1 functions as a tumor promoter in prostate cancer cells through EMT regulation
[J]. Genetics and Molecular Biology, 2020, 43(2).